Literature DB >> 15117327

Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection.

K Watt1, J Uhanova, Y Gong, K Kaita, K Doucette, N Pettigrew, G Y Minuk.   

Abstract

Recently, we documented that immunoglobulins stimulate the proliferative activity of rat hepatic stellate cells in vitro. The aim of the present study was to determine whether there is any association between serum immunoglobulin levels and hepatic fibrosis in patients with chronic hepatitis C virus (HCV) infection. Charts from 116 patients with biochemical, serologic, virologic and histologic evidence of chronic hepatitis C infection and serum immunoglobulin levels (IgA, IgG, IgM and total) were reviewed. The mean (+/-SD) age of the study population was 46 +/- 11 years and 67 (58%) were male. There were significant correlations between serum IgA (r = 0.39, P = 0.00001), IgG (r = 0.49, P = 0.000002) and total (r = 0.51, P = 0.000003) immunoglobulin levels and the stage of hepatic fibrosis. When serum immunoglobulin levels were included into logistic regression analysis with variables known to be associated with advanced disease (male gender, age >40 years at onset of infection, duration of infection beyond 20 years and concurrent alcohol abuse) only IgA, IgG and total immunoglobulin levels (P < 0.05, <0.05 and <0.005, respectively) emerged as independent predictors of hepatic fibrosis. Our data indicate a strong association between serum immunoglobulin levels (IgA, IgG and total) and hepatic fibrosis in patients with HCV infection. This finding supports the need to further investigate whether immunoglobulins independently promote disease progression in patients with chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117327     DOI: 10.1111/j.1365-2893.2004.00507.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  15 in total

1.  Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.

Authors:  Noriyuki Koyama; Tomoko Yamazaki; Yuka Kanetsuki; Jiro Hirota; Tomohide Asai; Yasuhide Mitsumoto; Masayuki Mizuno; Toshihide Shima; Yoshihiro Kanbara; Satoko Arai; Toru Miyazaki; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2017-10-30       Impact factor: 7.527

2.  Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients.

Authors:  Azuma Watanabe; Toshibumi Shimokawa; Mitsuhiko Moriyama; Fumihiko Komine; Shuichi Amaki; Yasuyuki Arakawa; Chisei Ra
Journal:  Immunogenetics       Date:  2006-10-11       Impact factor: 2.846

3.  Total serum glycan analysis is superior to lectin-FLISA for the early detection of hepatocellular carcinoma.

Authors:  Mary Ann Comunale; Mengjun Wang; Nikhil Anbarasan; Lucy Betesh; Aykan Karabudak; Ethan Moritz; Karthik Devarajan; Jorge Marrero; Timothy M Block; Anand Mehta
Journal:  Proteomics Clin Appl       Date:  2013-09-13       Impact factor: 3.494

4.  Effect of hepatitis C virus coinfection on humoral immune alterations in naïve HIV-infected adults on HAART: a three year follow-up study.

Authors:  Natalia Soriano-Sarabia; Manuel Leal; Carmen Delgado; Sonia Molina-Pinelo; Beatriz De Felipe; Ezequiel Ruiz-Mateos; Armando Sánchez-Quijano; Eduardo Lissen; Alejandro Vallejo
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

5.  C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study.

Authors:  Muhammed Emin Demirkol; Gulali Aktas; Satilmiş Bilgin; Gizem Kahveci; Ozge Kurtkulagi; Burcin Meryem Atak; Tuba Taslamacioglu Duman
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-06-24       Impact factor: 1.712

6.  GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics.

Authors:  Dieter Vanderschaeghe; Wouter Laroy; Erwin Sablon; Philippe Halfon; Annelies Van Hecke; Joris Delanghe; Nico Callewaert
Journal:  Mol Cell Proteomics       Date:  2009-01-29       Impact factor: 5.911

7.  Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease.

Authors:  Jordan J Feld; Nadeem Hussain; Elizabeth C Wright; David E Kleiner; Jay H Hoofnagle; Sushil Ahlawat; Victoria Anderson; Dianne Hilligoss; John I Gallin; T Jake Liang; Harry L Malech; Steven M Holland; Theo Heller
Journal:  Gastroenterology       Date:  2008-03-04       Impact factor: 22.682

8.  Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis.

Authors:  Anand S Mehta; Ronald E Long; Mary Ann Comunale; Mengjun Wang; Lucy Rodemich; Jonathan Krakover; Ramila Philip; Jorge A Marrero; Raymond A Dwek; Timothy M Block
Journal:  J Virol       Date:  2007-11-28       Impact factor: 5.103

9.  Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease.

Authors:  Wei Yuan; Miloslav Sanda; Jing Wu; John Koomen; Radoslav Goldman
Journal:  J Proteomics       Date:  2015-01-09       Impact factor: 4.044

10.  Elevated serum immunoglobulin G levels in patients with chronic liver disease in comparison to patients with autoimmune hepatitis.

Authors:  Hind I Fallatah; Hisham O Akbar
Journal:  Libyan J Med       Date:  2010-01-25       Impact factor: 1.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.